Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Merck

Pfizer

Snowflake

T-Mobile US

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.

Warren Buffett Just Bought These Stocks

AbbVie Inc. (ABBV) Presents at Wolfe Research Healthcare Conference (Transcript)

AbbVie reported strong Q3 results, the pandemic is not a major headwind for the company. Following another double-digit dividend raise, AbbVie's dividend yield is 5.2%.

5%-Yielding AbbVie: Double-Digit Dividend Raise And A Buffett Endorsement

ABBV is a large biopharmaceutical corporation whose main drug is Humira. ABBV acquired Allergan last year, which provided it with diversification, as well as more substantial size and scale.

AbbVie Should Benefit From A Buffett Bounce

NORTH CHICAGO, Ill., Nov. 18, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior...

AbbVie Announces Expiration and Final Results of Registered Exchange Offers

Warren Buffett's Berkshire Hathaway plowed more than $5 billion in total into AbbVie, Bristol Myers Squibb, Merck, and Pfizer in the third quarter. Close followers of the company won't be surprised, as Buffett has been mulling a bet on the pharmaceutical sector for more than 20 years. "You could've just bought the whole industry and done very well," the famed investor said at Berkshire's annual shareholder meeting in 1997. He was referring to the downturn in drug stocks in the early 1990s, sparked by President Bill Clinton's proposed healthcare reforms. "We didn't do it. It was a mistake."

Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years

The Oracle of Omaha and his investing lieutenants knew what they were doing in buying AbbVie, BMS, Merck, and Pfizer.

Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks

Berkshire Hathaway bought $5.7bn worth of shares in four companies in third quarter

Warren Buffett makes big investment in US pharmaceutical firms

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.

Has Buffett Become an Expert on Big Pharma?

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.

AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter

Warren Buffett is ditching bank stocks and loading up on drug makers, according to Berkshire Hathaway's latest regulatory filing. The post Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks appeared first on InvestorPlace.

Buffett's Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) Chairman Warren Buffett has invested in four large drugmakers as the world faces yet another wave of the raging COVID-19 pandemic. What Happened: Regulatory filings made with the United States Securities and Exchange Commission reveal that the legendary investor picked up shares worth nearly $136 million in drugmaker Pfizer Inc (NYSE: PFE) in the latest quarter.

Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic

The Oracle of Omaha and his team opened new positions in the underperforming sector.

Warren Buffett Bought 4 Pharma Giants in Q3

Warren Buffett (Trades, Portfolio)'s $545.8 billion conglomerate, Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B), disclosed its equity portfolio for the third quarter of 2020 on Monday.

Warren Buffett Buys 6 Stocks in 3rd Quarter, Dumps Costco

Warren Buffett's Berkshire Hathaway is making a big bet on the health care sector at a time when the Covid-19 pandemic continues to be a major crisis in the United States.

Warren Buffett's Berkshire Hathaway makes big bets on drug stocks

Warren Buffett's Berkshire Hathaway invested in AbbVie, Bristol-Myers Squibb, Merck, and Pfizer in the third quarter. The billionaire investor's company disclosed the new holdings in a regulatory filing on Monday. Berkshire boasted stakes worth more than $1.8 billion in each of AbbVie, Bristol Myers Squibb, and Merck as of September 30. It also owned $136 million of Pfizer stock. Buffett and his team also trimmed their Apple stake, which is easily the most valuable holding in their stock portfolio. Visit Business Insider's homepage for more stories. Warren Buffett's Berkshire Hathaway plowed billions of dollars into Pfizer, Merck, and other pharmaceutical stocks in the third quarter, a regulatory filing revealed on Monday.

Warren Buffett's Berkshire Hathaway reveals stakes in AbbVie, Merck, Pfizer, and other 'big pharma' stocks

Warren Buffett's Berkshire Hathaway Inc said on Monday it has begun investing in four large drugmakers.

Buffett's Berkshire invests in several big drugmakers

Costco

Duke Energy

Investors worried about a recession should consider leading stocks in the utilities, basic consumer goods, and healthcare sectors.

3 Recession Proof Stocks to Buy Now

Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Is AbbVie (ABBV) a Suitable Stock for Value Investors Now?

Huntington Ingalls Industries

Nexstar Media Group

Snap-on

Tyson Foods

Sometimes investors think they need to choose between value and growth, you can have both. However, in dividend investing, you often have to choose between value, yield and growth.

Value Vs. Growth: Buy These 5 Top Dividend Stocks If You Want Both

Aspen Technology Inc

Alibaba

British American Tobacco

Cboe Global Markets

Cisco Systems

eBay

McKesson

Altria

Oracle

Polaris

Philip Morris

SEI Investments

T. Rowe Price Group

Optimism about effective vaccines coming soon have sent the market back to record highs, ending the pullback. For the rest of the year, the pandemic is expected to continue getting worse. JPMorgan estimates a 20% to 25% probability of a double-dip recession and a 22% bear market.

The 15 Highest Quality Blue Chips To Buy With Market At All-Time Highs

Cardinal Health

Canadian Imperial Bank of Commerce

Coca-Cola

Leggett & Platt

Realty Income Corp

Occidental Petroleum

Visa

In October, we (my wife and I) received a total of $839.12 of dividend income. We had two massive dividend payments that came in from Philip Morris and Canadian Imperial.

Dividend Income Summary: Lanny's October 2020 Summary

Comcast

CVS Health

Fiserv

Johnson & Johnson

Mondelez

Investors have been waiting for value stocks to catch up to growth stocks for a decade now, and some think they're seeing signs of the long-awaited rotation from pricey stocks to cheap ones. Value stocks had a heady few days in the second week of November when they trounced some of the biggest growth names in the market.

7 Best Value Stocks for the 'Great Rotation'

B&G Foods

FirstEnergy

Vici Properties

Investors have burned of late chasing high-yield dividend stocks. These 4 stocks with yields more than 5% should buck that trend.

4 Dividend Stocks With Yields Over 5%

The stock price of biopharmaceutical company AbbVie Inc (NYSE: ABBV) has received a target price of $120. These are the details.

News for AbbVie Stock (ABBV)